NON-COVALENT INHIBITION OF THE 26S PROTEASOME AND USES THEREOF

摘要

The present inventions relate to compositions and methods for treating inflammatory diseases and cancer by administering proteasome inhibitors. In particular, the present inventions provide a new class of orally available non-covalent proteasome inhibitors capable of reducing NF-kappaB for mediating cytokine production in vivo. Further, the use of a small molecular weight inhibitor of the 26S proteasome via a non-covalent type inhibition is contemplated for use as a means to treat NF -kB mediated diseases, including but not limited to multiple myeloma and rheumatoid arthritis.